Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

mRNA-based <i>in vivo</i> induction of ETV2 to restore blood flow in a preclinical mouse hindlimb ischemia model

Toyonaga H., Arai K., Zhang M., Cheng L., Tanaka H.

Animal Study on Peripheral Artery Disease, published in Mol Ther Nucleic Acids (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mol Ther Nucleic Acids (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40612712
PMCID
PMC12221739
DOI
10.1016/j.omtn.2025.102592

Abstract (original English)

Regenerative medicine aims to repair tissue defects and functional abnormalities by enhancing endogenous cellular processes. Additional to cell-based therapy, viral and nonviral gene therapies have raised substantial interest as promising approaches that allow the direct modulation of key signaling pathways for tissue regeneration in the body. E26 transformation-specific (ETS) variant transcription factor 2 (ETV2) is a well-validated transcription factor which enables vascular regeneration. The therapeutic efficacy of this factor was demonstrated using lentiviral-based in vivo transduction of ETV2 in a murine model of hindlimb ischemia (HLI). However, given the theoretical safety risks inherent to the clinical use of lentivirus, alternative approaches are considered desirable. Here, we investigated the use of a messenger RNA (mRNA)-based approach to in vivo induction of ETV2. Consistent with previous reports using ETV2 lentivirus, we show that ETV2 translated from synthetic mRNA promotes the upregulation of key endothelial genes in vitro . Furthermore, we demonstrate that the intramuscular injection of ETV2 mRNA encapsulated in lipid nanoparticle (LNP) induces local expression of ETV2 protein in skeletal muscle stromal cells and accelerates blood flow recovery in a murine HLI model. These results provide the first demonstration of ETV2 mRNA with LNP as a potential therapeutic t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research